Albazee Ebraheem, Alenezi Khaled, Alkandari Abdulwahab, Sahli Abdullah Al, Almulla Faisal, Alnowaishiri Khalaf A, Alwael Athari
Otorhinolaryngology-Head and Neck Surgery Kuwait Institute for Medical Specializations (KIMS) Kuwait City Kuwait.
Department of Otolaryngology-Head and Neck Surgery Al-Jahra Hospital Al-Jahra Kuwait.
OTO Open. 2025 Sep 19;9(3):e70166. doi: 10.1002/oto2.70166. eCollection 2025 Jul-Sep.
To evaluate the analgesic efficacy and safety of local anesthetic infiltration in the tonsillar fossa using ropivacaine compared to bupivacaine in pediatric patients undergoing tonsillectomy.
CENTRAL, PubMed, Web of Science, Scopus, and Google Scholar.
Eligible randomized controlled trials (RCTs) were evaluated for risk of bias using Cochrane's Risk of Bias Tool (RoB-2). The primary outcome was postoperative pain within the first 24 hours following tonsillectomy. Secondary outcomes included the time to first analgesic requirement and complication rates (ie, bleeding, airway obstruction, local anesthetic toxicity, and nausea). Data were synthesized using the standardized mean difference (SMD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes, both reported with 95% confidence intervals (CI).
Seven RCTs with a total of 375 patients were analyzed. Regarding posttonsillectomy pain scores, there was no significant difference between ropivacaine and bupivacaine at 1 hour (SMD = -0.01, 95% confidence interval [CI] [-0.36, 0.34]), 2 hours (SMD = 0.03, 95% CI [-0.45, 0.51]), 4 hours (SMD = -0.17, 95% CI [-0.39, 0.06]), 6-8 hours (SMD = 0.04, 95% CI [-0.38, 0.46]), and 12 hours (SMD = -0.23, 95% CI [-0.62, 0.15]). However, at 24 hours, ropivacaine demonstrated a superior effect compared to bupivacaine (SMD = -0.23, 95% CI [-0.43, -0.03]). There was no significant difference between ropivacaine and bupivacaine in terms of time to first analgesia and complication rates ( > .05).
This meta-analysis demonstrated that ropivacaine and bupivacaine offer comparable clinical analgesic efficacy and safety profiles in pediatric patients undergoing tonsillectomy.
比较在接受扁桃体切除术的儿科患者中,使用罗哌卡因与布比卡因进行扁桃体窝局部麻醉浸润的镇痛效果和安全性。
CENTRAL、PubMed、科学网、Scopus和谷歌学术。
使用Cochrane偏倚风险工具(RoB-2)评估符合条件的随机对照试验(RCT)的偏倚风险。主要结局是扁桃体切除术后24小时内的术后疼痛。次要结局包括首次需要镇痛的时间和并发症发生率(即出血、气道阻塞、局部麻醉药毒性和恶心)。连续结局使用标准化均数差(SMD)进行数据合并,二分结局使用风险比(RR)进行合并,两者均报告95%置信区间(CI)。
分析了7项共375例患者的RCT。关于扁桃体切除术后疼痛评分,罗哌卡因与布比卡因在1小时(SMD = -0.01,95%置信区间[CI][-0.36, 0.34])、2小时(SMD = 0.03,95% CI [-0.45, 0.51])、4小时(SMD = -0.17,95% CI [-0.39, 0.06])、6 - 8小时(SMD = 0.04,95% CI [-0.38, 0.46])和12小时(SMD = -0.23,95% CI [-0.62, 0.15])时无显著差异。然而,在24小时时,罗哌卡因显示出比布比卡因更好的效果(SMD = -0.23,95% CI [-0.43, -0.03])。罗哌卡因与布比卡因在首次镇痛时间和并发症发生率方面无显著差异(P > 0.05)。
这项荟萃分析表明,在接受扁桃体切除术的儿科患者中,罗哌卡因和布比卡因具有相当的临床镇痛效果和安全性。